Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EBT (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EBT for 13 consecutive years, with -$58.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 1.63% to -$58.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$285.0 million through Dec 2025, up 38.82% year-over-year, with the annual reading at -$285.0 million for FY2025, 38.82% up from the prior year.
  • EBT for Q4 2025 was -$58.4 million at Madrigal Pharmaceuticals, up from -$111.1 million in the prior quarter.
  • The five-year high for EBT was -$42.2 million in Q2 2025, with the low at -$152.0 million in Q2 2024.
  • Average EBT over 5 years is -$83.1 million, with a median of -$75.1 million recorded in 2023.
  • The sharpest move saw EBT plummeted 91.87% in 2024, then skyrocketed 72.21% in 2025.
  • Over 5 years, EBT stood at -$64.5 million in 2021, then plummeted by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.04% to -$59.4 million in 2024, then rose by 1.63% to -$58.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$58.4 million, -$111.1 million, and -$42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.